Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 25   

Articles published

AZN 5,149.98 -2.02 (-0.04%)
price chart
Astra takes brand cancer drug straight to patients
(Reuters) - AstraZeneca Plc is selling breast cancer drug Arimidex directly to U.S. patients, offering an option for people who want to pay for the brand instead of generic versions.
AstraZeneca closing Montreal R&D plant
British drug maker AstraZeneca is closing its Montreal research centre as part of a global move to cut costs and improve its productivity as it warned of a tough year ahead.
AstraZeneca India job cuts likely to hurt drug research
New Delhi: Theextensive layoffs at London-listed drug maker AstraZeneca Plc's research outfits have hit India. On 13 February, the firm's Bangalore subsidiary laid off 19 employees—15 of them middle-level and senior scientists involved in the research ...
Special Report: A prescription for corruption
Officials at drugs companies AstraZeneca Plc, Sanofi SA and Actavis confirmed they were served in July and August 2011 with criminal indictments related to allegedly improper payments to physicians including Borojevic at his state-run institute, and ...
Pfizer eyes tie-ups with more Chinese drugmakers
Apart from Pfizer, drugmakers like AstraZeneca Plc (AZN.L), Abbott Laboratories (ABT.N) and Novartis AG NOVN.VX are taking advantage of China's lower costs and enormous pool of scientists to make big investments in R&D in China in recent years.
Debt crisis: as it happened, February 3, 2012
This come on top of annoucements on Thursday from AstraZeneca and Smith & Nephew that they are cutting 7,300 and 800 jobs respectively.
GSK brings work in-house in bid to boost efficiency and cut costs
News of supply chain optimisation efforts at GSK comes the week after fellow UK giant AstraZeneca outlined plans to eliminate 1,350 operations jobs.
Celgene Executive Dr Rajesh Chopra Joins the Board of e-Therapeutics
Before joining Celgene, he spent five years at AstraZeneca in the US and the UK, culminating in the role of Medical Science Director, Senior Principal Scientist and Disease Area Team Leader for blood cancers.
Sedona Conference Issues International Principles On Discovery And Data Protection
Rexam PLC, No.1:10CV511 (GBL/TRJ), 2010 WL 5574325, at *2, n.1 (E.D. Va. ... [6] See, e.g., AstraZeneca LP v. Breath Ltd.
Cambridge technology cluster thriving thanks to university dynamism
Cambridge Antibody Technology was subsequently acquired by AstraZeneca in 2006 for �702m and merged into MedImmune, which retains a major operation in Cambridge.